# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

> **NCT04685265** · PHASE1 · COMPLETED · sponsor: **MODAG GmbH** · enrollment: 70 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** anle138b
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04685265
- **Lead sponsor:** MODAG GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-12-22
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-03-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04685265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04685265, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04685265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*